Table 4. Values for SSFs Among 2010 Cases^a.

	Code	Total Cases	Percent of Total Cases
SSF 1: WHO/ISUP Gradeb
Low-grade urothelial (transitional cell) carcinoma	10	6037	35.3%
High-grade urothelial (transitional cell) carcinoma	20	7949	46.5%
Not collected	998	248	1.5%
Unknown	999	2845	16.7%
TOTAL		17 079	100.0%
SSF2: Size of Metastases in Regional Lymph Nodesc
No regional lymph nodes involved	000	12	1.7%
Exact size coded (1-979 mm, 980+) or range given	1-979, 980	284	41.3%
	990-997
Unknown	999	391	56.9%
TOTAL		687	100.0%
SSF3: Extranodal Extensionc
No regional lymph nodes involved	00	54	7.9%
Extranodal extension not present Regional nodes described as mobile	10	187	27.2%
Extranodal extension present Regional nodes described as fixed or matted	20	67	9.8%
Regional nodes involved, unknown if extranodal extension	30	288	41.9%
Unknown; regional lymph nodes not stated Regional lymph nodes cannot be assessed Not documented in patient record	999	91	13.3%
TOTAL		687	100.0%

Abbreviations: CS, Collaborative Staging; ISUP, International Society of Urological Pathology; mm, millimeters; SSFs, site-specific factors;WHO, World Health Organization.

^aIncludes both noninvasive and invasive cases.

^bCases that were not considered urothelial (transitional cell) were excluded.

^cCases with CS Lymph Node values of no involvement (00) or unknown involvement (99) were excluded.